FDA Approves Voranigo for Grade 2 Astrocytoma or Oligodendroglioma
By Lori Solomon HealthDay Reporter
FRIDAY, Aug. 9, 2024 -- The U.S. Food and Drug Administration has approved Voranigo (vorasidenib) for grade 2 astrocytoma or oligodendroglioma with a susceptible mutation.
The isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor is approved for adult and pediatric patients ages 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation (determined by the Life Technologies Corporation Oncomine Dx Target Test) following surgery, including biopsy, subtotal resection, or gross total resection.
The approval was based on a trial of 331 patients randomly assigned (1:1) to receive Voranigo (40 mg orally once daily) or placebo orally once daily until disease progression or unacceptable toxicity. Results showed a significantly lower risk for progression-free survival with Voranigo (hazard ratio, 0.39). The median time to next intervention was 17.8 months in the placebo arm but was not reached in the Voranigo arm (hazard ratio, 0.26). The most common (≥15 percent) adverse reactions included fatigue, headache, COVID-19 infection, musculoskeletal pain, diarrhea, nausea, and seizure, while the most common grade 3 or 4 laboratory abnormalities (>2 percent) were increased alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyl transferase and decreased neutrophils.
"The possibility of delaying radiation therapy and chemotherapy with this drug could be beneficial to select patients with slow growing IDH-mutant gliomas," Matthias Holdhoff, M.D., Ph.D., from the Johns Hopkins Kimmel Cancer Center, and co-investigator on the 2023 clinical trial, said in a statement. "I believe we are looking at a new standard of care option for these types of tumors."
Approval of Voranigo was granted to Servier Pharmaceuticals.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Tumor-Related Epilepsy Not Strong Prognostic Factor in Diffuse Glioma
WEDNESDAY, May 21, 2025 -- For patients with diffuse gliomas, tumor-related epilepsy (TRE) is not a strong prognostic factor, according to a study published in the May issue of...
Mutational Signatures Tied to Haloalkane Exposure Are Enriched in Firefighters
MONDAY, March 10, 2025 -- In a study published online March 10 in Cancer, authors identified gliomas with mutational signatures associated with haloalkane exposure in individuals...
Hormone Therapy Not Associated With Glioma Risk in Women
WEDNESDAY, Jan. 15, 2025 -- There seems to be no association between hormone therapy (HT) and glioma risk among U.S. women, according to a study published online Jan. 14 in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.